Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites.

Nobilis M, Mikušek J, Szotáková B, Jirásko R, Holčapek M, Chamseddin C, Jira T, Kučera R, Kuneš J, Pour M.

J Pharm Biomed Anal. 2013 Jun;80:164-72. doi: 10.1016/j.jpba.2013.03.006. Epub 2013 Mar 19.

PMID:
23584048
2.

Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection.

Nobilis M, Kopecký J, Kvetina J, Svoboda Z, Pour M, Kunes J, Holcapek M, Kolárová L.

J Pharm Biomed Anal. 2003 Aug 8;32(4-5):641-56.

PMID:
12899954
3.
4.

[Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection].

Nespesná L, Stícha M, Matousková O, Perlík F, Slanar O.

Ceska Slov Farm. 2011 Feb;60(1):17-24. Czech.

PMID:
21650014
5.

Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery.

Miehlke RK, Schneider S, Sörgel F, Muth P, Henschke F, Giersch KH, Münzel P.

Drugs. 1990;40 Suppl 5:57-61.

PMID:
2081495
6.

Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.

Kumpulainen H, Mähönen N, Laitinen ML, Jaurakkajärvi M, Raunio H, Juvonen RO, Vepsäläinen J, Järvinen T, Rautio J.

J Med Chem. 2006 Feb 9;49(3):1207-11.

PMID:
16451086
7.

A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.

Turpeinen M, Hofmann U, Klein K, Mürdter T, Schwab M, Zanger UM.

Drug Metab Dispos. 2009 May;37(5):1017-24. doi: 10.1124/dmd.108.025700. Epub 2009 Feb 9.

8.

High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study.

Patel BN, Sharma N, Sanyal M, Prasad A, Shrivastav PS.

Biomed Chromatogr. 2008 Nov;22(11):1213-24. doi: 10.1002/bmc.1047.

PMID:
18651608
9.

[Determination of 6-methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human plasma by HPLC].

Qin Y, Zou Y, Liang M, Huang Y, Yu Q.

Hua Xi Yi Ke Da Xue Xue Bao. 1999 Dec;30(4):452-4. Chinese.

PMID:
11387968
10.

Effect of the antiinflammatory prodrug, nabumetone and its principal active metabolite on rat gastric mucosal, aortic and platelet eicosanoid synthesis, in vitro and ex vivo.

Jeremy JY, Thompson CS, Mikhailidis DP, Dandona P.

Prostaglandins Leukot Essent Fatty Acids. 1990 Nov;41(3):195-9.

PMID:
2281122
11.

A novel injection strategy of flurbiprofen axetil by inhibiting protein binding with 6-methoxy-2-naphthylacetic acid.

Ogata K, Takamura N, Tokunaga J, Ikeda T, Setoguchi N, Tanda K, Yamasaki T, Nishio T, Kawai K.

Eur J Drug Metab Pharmacokinet. 2016 Apr;41(2):179-86. doi: 10.1007/s13318-014-0248-z. Epub 2014 Dec 24.

PMID:
25537338
12.

Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses.

Soma LR, Uboh CE, Rudy JA, Smith MS.

Am J Vet Res. 1996 Apr;57(4):517-21.

PMID:
8712517
13.
14.

Nabumetone. Evidence for the lack of enterohepatic circulation of the active metabolite 6-MNA in humans.

Brett MA, Buscher G, Ellrich E, Greb WH, Kurth HJ, Rülander G, Schmerenbeck B, Haddock RE, Thawley AR.

Drugs. 1990;40 Suppl 5:67-70. No abstract available.

PMID:
2081498
15.

Carbon-carbon bond cleavage in activation of the prodrug nabumetone.

Varfaj F, Zulkifli SN, Park HG, Challinor VL, De Voss JJ, Ortiz de Montellano PR.

Drug Metab Dispos. 2014 May;42(5):828-38. doi: 10.1124/dmd.114.056903. Epub 2014 Feb 28.

16.
17.

Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro.

Skarydova L, Nobilis M, Wsól V.

Xenobiotica. 2013 Apr;43(4):346-54. doi: 10.3109/00498254.2012.720048. Epub 2012 Sep 28.

PMID:
23020786
18.

Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.

Hedner T, Samulesson O, Währborg P, Wadenvik H, Ung KA, Ekbom A.

Drugs. 2004;64(20):2315-43; discussion 2344-5. Review.

PMID:
15456329
19.
20.

Simultaneous determination of nabumetone and its principal metabolite in medicines and human urine by time-resolved fluorescence.

Murillo Pulgarín JA, Alañón Molina A, Martínez Ferreras F.

Analyst. 2012 Nov 7;137(21):5144-52. doi: 10.1039/c2an35412h. Epub 2012 Sep 13.

PMID:
22977877

Supplemental Content

Support Center